| Year |
Citation |
Score |
| 2020 |
Wu H, Zhu K, Tu X, Albu D, Woodall-Jappe M, Littlefield BA. Abstract 5522: Evaluation of eribulin-induced alterations of the intact immune cell landscape in spleens and tumors from tumor-bearing immunocompetent mice Immunology. DOI: 10.1158/1538-7445.Am2020-5522 |
0.468 |
|
| 2019 |
Huang K, Endo A, McGrath S, Chandra D, Wu J, Kim D, Albu D, Ingersoll C, Tendyke K, Loiacono K, Noland T, Verbel D, Zhang C, Hao M, Matijevic M, et al. Abstract 3269: Discovery and characterization of E7766, a novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through intravesical and intratumoral administration Cancer Research. 79: 3269-3269. DOI: 10.1158/1538-7445.Am2019-3269 |
0.464 |
|
| 2017 |
Albu DI, Wang Z, Huang KC, Wu J, Twine N, Leacu S, Ingersoll C, Parent L, Lee W, Liu D, Wright-Michaud R, Kumar N, Kuznetsov G, Chen Q, Zheng W, et al. EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity. Oncoimmunology. 6: e1338239. PMID 28920002 DOI: 10.1080/2162402X.2017.1338239 |
0.558 |
|
| 2017 |
Albu DI, Verbel D, Huang Y, Kolber-Simonds D, Wang Z, Wang X, Dezso Z, Ingersoll C, Huang K, Hutz J, Woodall-Jappe M, Bao X. Abstract 4607: Specific inhibition of PGE2-EP4 signaling by E7046 promotes anti-tumor activity of checkpoint blockade agents through boosting cytotoxic T cell activity Cancer Research. 77: 4607-4607. DOI: 10.1158/1538-7445.Am2017-4607 |
0.523 |
|
| 2017 |
Albu DI, Ingersoll C, Huang K, Woodall-Jappe M, Bao X. Abstract 4586: Intratumoral Treg cell depletion by local administration of IL-2-Diphteria toxin fusion protein E7777 induces a therapeutic and memory anti-tumor immune response in preclinical models Cancer Research. 77: 4586-4586. DOI: 10.1158/1538-7445.Am2017-4586 |
0.567 |
|
| 2016 |
Bao X, Albu DI, Huang KC, Wu J, Twine N, Nomoto K, Woodall-Jappe M, Ataman O. Combination of a Novel EP4 Antagonist E7046 and Radiation Therapy Promotes Anti-tumor Immune Response and Tumor Rejection in Preclinical Tumor Models. International Journal of Radiation Oncology, Biology, Physics. 96: S128. PMID 27675592 DOI: 10.1016/J.Ijrobp.2016.06.312 |
0.466 |
|
| 2016 |
Albu DI, Huang K, Wu J, Bao X, Nomoto K, Woodall-Jappe M. Abstract B034: Preclinical immune antitumor activity of myeloid-targeting E7046 and Treg depleting E7777 Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B034 |
0.572 |
|
| 2015 |
Bao X, Albu D, Huang K, Wu J, Twine N, Nomoto K, Woodall-Jappe M. Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models Journal For Immunotherapy of Cancer. 3: 350. DOI: 10.1186/2051-1426-3-S2-P350 |
0.556 |
|
| 2015 |
Albu DI, Wang Z, Wu J, Huang K, Li W, Liu D, Kuznetsov G, Chen Q, Bao X, Woodall-Jappe M. Abstract 275: ER-886046, an antagonist of PGE2 receptor type-4, induces an effective antitumor immune response in mice by attenuating intratumoral MDSCs and TAMs Cancer Research. 75: 275-275. DOI: 10.1158/1538-7445.Am2015-275 |
0.511 |
|
| 2015 |
Albu DI, Wu J, Huang K, Wright-Michaud R, Xu S, Kuznetsov G, Bao X, Woodall-Jappe M. Abstract B198: Pharmacological profile of the PGE2EP4 receptor antagonist E7046 Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B198 |
0.477 |
|
| 2013 |
Albu DI, Kumar N, Kusnetzov G, Xu S, Littlefield B, Woodall-Jappe M. Abstract B90: Eribulin mesylate alters immune homeostasis in mice bearing syngeneic tumors. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-B90 |
0.547 |
|
| 2013 |
Albu DI, Littlefield BA, Woodall-Jappe M. Abstract 1227: Macrophage depletion enhances the anticancer efficacy of eribulin mesylate in mice bearing syngeneic tumors. Cancer Research. 73: 1227-1227. DOI: 10.1158/1538-7445.Am2013-1227 |
0.43 |
|
| 2011 |
Vanvalkenburgh J, Albu DI, Bapanpally C, Casanova S, Califano D, Jones DM, Ignatowicz L, Kawamoto S, Fagarasan S, Jenkins NA, Copeland NG, Liu P, Avram D. Critical role of Bcl11b in suppressor function of T regulatory cells and prevention of inflammatory bowel disease. The Journal of Experimental Medicine. 208: 2069-81. PMID 21875956 DOI: 10.1084/Jem.20102683 |
0.404 |
|
| 2011 |
Albu DI, VanValkenburgh J, Morin N, Califano D, Jenkins NA, Copeland NG, Liu P, Avram D. Transcription factor Bcl11b controls selection of invariant natural killer T-cells by regulating glycolipid presentation in double-positive thymocytes. Proceedings of the National Academy of Sciences of the United States of America. 108: 6211-6. PMID 21444811 DOI: 10.1073/Pnas.1014304108 |
0.445 |
|
| 2010 |
Albu DI, Califano D, Avram D. Flow cytometry analysis of transcription factors in T lymphocytes. Methods in Molecular Biology (Clifton, N.J.). 647: 377-90. PMID 20694680 DOI: 10.1007/978-1-60761-738-9_23 |
0.347 |
|
| 2010 |
Zhang S, Rozell M, Verma RK, Albu DI, Califano D, VanValkenburgh J, Merchant A, Rangel-Moreno J, Randall TD, Jenkins NA, Copeland NG, Liu P, Avram D. Antigen-specific clonal expansion and cytolytic effector function of CD8+ T lymphocytes depend on the transcription factor Bcl11b. The Journal of Experimental Medicine. 207: 1687-99. PMID 20660613 DOI: 10.1084/Jem.20092136 |
0.427 |
|
| 2007 |
Albu DI, Feng D, Bhattacharya D, Jenkins NA, Copeland NG, Liu P, Avram D. BCL11B is required for positive selection and survival of double-positive thymocytes. The Journal of Experimental Medicine. 204: 3003-15. PMID 17998389 DOI: 10.1084/Jem.20070863 |
0.312 |
|
| 2006 |
Cismasiu VB, Ghanta S, Duque J, Albu DI, Chen HM, Kasturi R, Avram D. BCL11B participates in the activation of IL2 gene expression in CD4+ T lymphocytes. Blood. 108: 2695-702. PMID 16809611 DOI: 10.1182/Blood-2006-05-021790 |
0.405 |
|
| 2003 |
Albu DI, Jones-Trower A, Woron AM, Stellrecht K, Broder CC, Metzger DW. Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. Journal of Virology. 77: 5589-97. PMID 12719551 DOI: 10.1128/Jvi.77.10.5589-5597.2003 |
0.456 |
|
| Show low-probability matches. |